Related Experiment Video
Updated: Jul 8, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Danazol therapy in myelodysplasia
Danazol therapy increased platelet counts and stopped bleeding in patients with myelodysplastic syndromes and severe thrombocytopenia. This suggests danazol may be effective for managing transfusion-refractory thrombocytopenia, potentially by affecting macrophage clearance.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) can cause severe thrombocytopenia.
- Thrombocytopenia in these patients is often refractory to platelet transfusions.
- Elevated platelet-associated IgG suggests an immune-mediated destruction of platelets.
Observation:
- Three patients with MDS and severe, transfusion-refractory thrombocytopenia were treated with danazol.
- Danazol was chosen due to its known efficacy in immune thrombocytopenic purpura (ITP).
Findings:
- Following danazol treatment, all three patients experienced increased platelet counts.
- Clinical bleeding ceased in all patients.
- Two patients showed a reduction in hemolysis.
- Danazol's mechanism may involve impeding macrophage-mediated platelet clearance, though a direct effect on hematopoiesis is possible.
Implications:
- Danazol may represent a therapeutic option for managing severe, refractory thrombocytopenia in MDS.
- Further research is warranted to elucidate danazol's precise mechanisms in this context.
- Understanding danazol's effects could lead to improved treatment strategies for MDS-related complications.
Related Concept Videos
Drugs that Stabilize Microtubules
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

